SpaceX Fell 3.9% on Its Third Lockup Release Since the IPO. I'd Wait to Buy the Stock.

SpaceX fell 3.9% to $147.55 as up to 319 million shares were released from lockup, with another 3.1 billion shares scheduled to become tradeable by early December. Only about 2.2 billion of 13.6 billion shares outstanding, or 17%, are currently eligible to trade; a 1.3 billion-share unlock is due shortly after Q3 results. The company trades near a $2 trillion valuation, or more than 60x annualized Q2 revenue of roughly $31 billion, despite Q2 revenue nearly doubling to $7.8 billion and a $541 million net loss. Expected Nasdaq-100 rebalancing demand could drive an estimated $15.5 billion of index-fund buying, but substantial pending supply and elevated valuation underpin a cautious view.

Analysis

SPCX is entering a market-structure regime in which marginal pricing is set by a thin public float while the effective supply overhang is multiples of current tradable shares. The near-term Nasdaq-100 rebalance creates a mechanical bid, but it is a one-off liquidity event rather than a fundamental rerating; passive demand may provide an attractive window to establish downside exposure before the much larger post-earnings release. Elevated capex relative to revenue means that even rapid top-line growth does not yet translate into self-funding economics, leaving the valuation unusually sensitive to any deceleration in revenue growth or increase in launch/AI-infrastructure spending.

The key second-order issue is employee and early-investor behavior. A highly appreciated, concentrated private-market holding typically produces staggered diversification sales rather than a single-day volume shock, especially if the stock remains near highs. That creates persistent offer pressure through December and can suppress upside even if operational results meet expectations. Conversely, a clean absorption of the post-Q3 unlock, evidenced by stable VWAP and rising institutional ownership, would invalidate the technical short thesis and signal that scarcity-driven demand remains dominant.

Consensus may overstate the certainty of unlock-related declines: index inclusion flows and increased borrow availability can improve liquidity and broaden the buyer base. The more durable bearish catalyst is not the next scheduled release itself, but a Q3 result that shows capex intensity failing to decline, operating losses persisting, or revenue growth slipping below the level implied by the current revenue multiple. Over 6-18 months, a credible path to positive free cash flow could sustain a premium; absent that, the stock is vulnerable to multiple compression even with strong growth.

Key Decisions for Investors

• Do not chase SPCX into the Sept. 21 index-rebalance bid; use any flow-driven strength to initiate a 1-3 month tactical short or put spread, sized modestly given potential scarcity squeezes. Prefer post-rebalance entry rather than trading the Sept. 24 unlock mechanically.
• For defined risk, buy SPCX December put spreads after the passive-flow window, targeting exposure through the Q3 report and subsequent large unlock. Thesis requires a material decline in the sales multiple or evidence of sustained secondary selling; exit if shares hold above the post-rebalance high on strong volume and Q3 guidance improves.
• Pair long NVDA / short SPCX for a 3-6 month horizon: NVDA has liquid public-float price discovery and earnings-backed AI monetization, while SPCX carries float-expansion and capital-intensity risk. Hedge the pair if AI capex guidance broadly weakens, which would pressure both legs.
• Set a watch trigger rather than adding outright exposure: if Q3 operating loss narrows materially while capex/revenue declines and SPCX absorbs the large release at or above its 20-day VWAP, cover tactical shorts and reassess the structural valuation thesis.